Abstract
There are two major routes for clearance of aberrant cellular components: (i) the ubiquitin-proteasomal system (UPS); and (ii) the autophagy pathway. The UPS degrades individual abnormal proteins, whereas the autophagy pathway is the chief route for bulk degradation of large abnormal protein aggregates and aberrant organelles. Impairments of the protein degradation pathways are closely tied with many human diseases. Brain ischemia leads to protein misfolding and aggregation, resulting in overproduction of protein aggregate-associated organelles. Brain ischemia also damages protein degradation pathways. This chapter will discuss molecular mechanisms underlying the impairments of the UPS and autophagy pathways and how such impairments lead to multiple organelle failure and delayed neuronal death after brain ischemia.
Keywords: ubiquitin, microtubule-associated protein 1 light chain 3 (LC3), delayed neuronal death, autophagy, autophagosome, lysosome, protein aggregation, protein folding, organelle damage, global ischemia, focal ischemia
Current Drug Targets
Title: Protein Degradation Pathways after Brain Ischemia
Volume: 13 Issue: 2
Author(s): Pengfei Ge, Fan Zhang, Jingwei Zhao, Chunli Liu, Liankun Sun and Bingren Hu
Affiliation:
Keywords: ubiquitin, microtubule-associated protein 1 light chain 3 (LC3), delayed neuronal death, autophagy, autophagosome, lysosome, protein aggregation, protein folding, organelle damage, global ischemia, focal ischemia
Abstract: There are two major routes for clearance of aberrant cellular components: (i) the ubiquitin-proteasomal system (UPS); and (ii) the autophagy pathway. The UPS degrades individual abnormal proteins, whereas the autophagy pathway is the chief route for bulk degradation of large abnormal protein aggregates and aberrant organelles. Impairments of the protein degradation pathways are closely tied with many human diseases. Brain ischemia leads to protein misfolding and aggregation, resulting in overproduction of protein aggregate-associated organelles. Brain ischemia also damages protein degradation pathways. This chapter will discuss molecular mechanisms underlying the impairments of the UPS and autophagy pathways and how such impairments lead to multiple organelle failure and delayed neuronal death after brain ischemia.
Export Options
About this article
Cite this article as:
Ge Pengfei, Zhang Fan, Zhao Jingwei, Liu Chunli, Sun Liankun and Hu Bingren, Protein Degradation Pathways after Brain Ischemia, Current Drug Targets 2012; 13 (2) . https://dx.doi.org/10.2174/138945012799201694
DOI https://dx.doi.org/10.2174/138945012799201694 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells
Current Drug Delivery The Impact of Small Heat Shock Proteins (HspBs) in Alzheimer’s and Other Neurological Diseases
Current Pharmaceutical Design Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy Increased Expression of Matrix Metalloproteinases Mediates Thromboxane A2-Induced Invasion in Lung Cancer Cells
Current Cancer Drug Targets Glycoconjugates: Roles in Neural Diseases Caused by Exogenous Pathogens
CNS & Neurological Disorders - Drug Targets Evaluation of Venom as a Promising Tool for Drug Discovery: Focusing on Neurological Disorders
Venoms and Toxins Functional Roles of the Ca2+-activated K+ Channel, KCa3.1, in Brain Tumors
Current Neuropharmacology Tumor Stroma Manipulation By MSC
Current Drug Targets Endostatin: Preclinical Development as an Anticancer Agent
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Activatable Optical Probes for the Detection of Enzymes
Current Organic Synthesis Immuno-Isolation in Oncology - A Mini-Review
Current Pharmaceutical Biotechnology Novel Natural and Synthetic Ligands of the Endocannabinoid System
Current Medicinal Chemistry Relationship with Programmed Cell Death Ligand 1 (PD-L1) and DTI Features in Brain Metastases of Non-small Cell Lung Cancer: A Preliminary Study
Current Medical Imaging Overview of PCTK3/CDK18: A Cyclin-Dependent Kinase Involved in Specific Functions in Post-Mitotic Cells
Current Medicinal Chemistry TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Prognostic and Therapeutic Implications of MicroRNA in Malignant Pleural Mesothelioma
MicroRNA Current Experimental, Bioinformatic and Statistical Methods used in NMR Based Metabolomics
Current Metabolomics Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment
Current Cancer Drug Targets Novel Strategies to Discover Effective Drug Targets in Metabolic and Immune Therapy for Glioblastoma
Current Cancer Drug Targets